Novel filamin C (FLNC) variant causes a severe form of familial mixed hypertrophic-restrictive cardiomyopathy.
Nathalie GaudreaultLouis-Jacques RuelCyndi HenryJennifer SchleitPatrick LagüeJean ChampagneMario SénéchalJean-François SarrazinFrançois PhilipponYohan BosséChristian SteinbergPublished in: American journal of medical genetics. Part A (2023)
Variants of filamin C (FLNC) have been identified as rare genetic substrate for hypertrophic cardiomyopathy (HCM). Data on the clinical course of FLNC-related HCM are conflicting with some studies suggesting mild phenotypes whereas other studies have reported more severe outcomes. In this study, we present a novel FLNC variant (Ile1937Asn) that was identified in a large family of French-Canadian descent with excellent segregation data. FLNC-Ile1937Asn is a novel missense variant characterized by full penetrance and poor clinical outcomes. End stage heart failure requiring transplantation occurred in 43% and sudden cardiac death in 29% of affected family members. Other particular features of FLNC-Ile1937Asn include an early disease onset (mean age of 19 years) and the development of a marked atrial myopathy (severe biatrial dilatation with remodeling and multiple complex atrial arrhythmias) that was present in all gene carriers. The FLNC-Ile1937Asn variant is a novel, pathogenic mutation resulting in a severe form of HCM with full disease penetrance. The variant is associated with a high proportion of end-stage heart failure, heart transplantation, and disease-related mortality. Close follow-up and appropriate risk stratification of affected individuals at specialized heart centers is recommended.
Keyphrases
- hypertrophic cardiomyopathy
- heart failure
- left ventricular
- early onset
- atrial fibrillation
- copy number
- left atrial
- late onset
- genome wide
- cardiac resynchronization therapy
- gene expression
- machine learning
- acute heart failure
- mitral valve
- artificial intelligence
- dna methylation
- case control
- cell therapy
- mesenchymal stem cells
- bone marrow
- coronary artery disease